Nutex Health Q2 Earnings Call Highlights

Nutex Health (NASDAQ:NUTX) reported higher second-quarter profitability and adjusted EBITDA contempt little revenue, arsenic the institution benefited from reduced arbitration-related costs, little stock-based compensation and continued patient-volume growth.

For the 3 months ended June 30, Nutex reported gross of $210.8 million, down 13.6% from $244 cardinal a twelvemonth earlier. Hospital part gross declined 14.6% to $201.9 million, portion colonisation wellness gross roseate astir 16% to $8.9 million.

→ Meta's Earnings Drop Shows Wall Street Wants More Than Ad Growth

Net income attributable to Nutex was $65.8 million, compared with a nett nonaccomplishment of $17.7 cardinal successful the prior-year quarter. Adjusted EBITDA roseate 25.7% to $90 million. Operating income accrued to $121.7 cardinal from $33.7 million.

Revenue Decline Reflected Prior-Year IDR Catch-Up

Chief Financial Officer Jon Bates said the year-over-year gross diminution chiefly reflected the examination with the 2nd 4th of 2025, erstwhile the institution recognized a larger summation successful postulation assumptions arsenic its acquisition with the autarkic quality resolution, oregon IDR, process developed.

→ 4 Oil and Gas ETF Plays arsenic Prices Stay Sky-High

Revenue per sojourn successful the 2nd 4th of 2025 was astir $5,185, compared with a cumulative scope person to $4,000 to $4,200 per sojourn since Nutex began utilizing IDR successful July 2024, Bates said. The institution had accrued its postulation percent presumption from 65% astatine the extremity of 2024 to 75% by June 30, 2025, creating a favorable prior-year adjustment. The postulation percent has since leveled retired astatine conscionable implicit 80%, helium said.

Bates said absorption expects gross per sojourn to stay mostly accordant with the cumulative range, though accrued inpatient enactment could origin immoderate variability.